| Autor: |
Huan, Wang, Xin, Zhou, Jian-Wei, Zhu, Jian-Nan, Ye, Jian-Yong, Li, Chao, Sun |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Zhongguo shi yan xue ye xue za zhi. 27(5) |
| ISSN: |
1009-2137 |
| Popis: |
To retrospectively analyze the cases of multiple myeloma treated with chemotherapeatic regimens based on thalidomide, and to investigate the factors affecting MM patients treated using chemotherapeutic regimens with or without bortezomib.The clinical, laboratorial and survival data of 200 patients with newly diagnosed MM from October 2007 to December 2015 were collected, and the correlation of clinical and laboratorial indicators with the clinical characteristics and prognosis of MM patients was analyzed by using χMultivariable analysis showed that age (≥65 years old), ISS staging (Ⅲ), complex karyotypes and no-complete remission were the independent prognostic factors for OS in bortezomib-treated group, while the βThe differences of prognostic factors exist in MM patients treated with different chemotherapeutic regimens, moreover, the patients with comples karyotypes and no-complete remisson have poor prognosis. The MPI as more simple and easy clinical parameter, may be come an useful and complemental method for evaluation of prognosis except ISS and R-ISS.初诊非造血干细胞移植的多发性骨髓瘤患者预后因素的长期回顾性分析.对以沙利度胺为基础治疗方案的MM病例进行回顾性分析，探讨含或不含硼替佐米的治疗方法下影响MM患者的预后因素是否不同.收集本院2007年10月至2015年12月200例初诊MM患者的临床实验室各项指标及活存情况，采用χ多因素分析显示，硼替佐米组中年龄、ISS分期、复杂核型、完全缓解是OS的独立预后因素；传统治疗组中，β新老化疗方案治疗MM患者的预后因素存在差异，但复杂核型及未达完全缓解的MM患者预后均较差。MPI作为较简易的临床参数，或许可成为除了ISS及R-ISS以外有用的补充预后判别手段. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
